Improved care of rhabdomyosarcoma in Jordan using less intensive therapy

Usama Al-Jumaily, Omar Ayyad, Main Masarweh, Khalil Ghandour, Abdelatif Almousa, Maysa Al-Hussaini, Andrea Ferrari, Iyad Sultan

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: The care of rhabdomyosarcoma (RMS) is complex due to its multimodal nature. By following standard protocols with acceptable toxicity and building local expertise, better outcome should be achievable. Procedure: A retrospective study was conducted of records of patients (n=45; 31 males; median age 26 months) with RMS treated at King Hussein Cancer Center in Jordan from January 2004 to December 2008. Patient demographics, tumor characteristics, risk stratification, treatment plan, and outcomes were studied. In June 2006, the cyclophosphamide dose was lowered from 2.2g/m2 to 1.2g/m2 per cycle because of the significant toxicity with higher dose. Survival rates, hematological toxicities, period of hospitalization due to febrile neutropenia (FN), and response rate at week 12 of treatment were compared between low- and high-dose cyclophosphamide groups. Results: Four-year progression-free survival (PFS) and overall survival (OS) rates were 61%±7.5% and 72%±6.9%, respectively. There was a significant difference in outcome by risk group in 4-year PFS (low-risk, 88%±12%; intermediate-risk 63%±9.3%; high-risk, 14%±13%; P=0.0001) and OS (low-risk, 88%±12%; intermediate-risk 79%±7.5%; high-risk, 17%±15%; P=0.0011). There was significant reduction in hematological toxicities, incidence of FN, and period of hospitalization for FN in patients given low-dose cyclophosphamide but no significant difference in PFS between low- and high-dose cyclophosphamide groups. Conclusions: Survival rates of patients with RMS in some developing countries can be improved by following or modifying evidence-based approaches successful in developed countries and establishing multidisciplinary strategies. Therapy intensity should be increased in developing countries only when evidence supports its utility.

Original languageEnglish
Pages (from-to)53-58
Number of pages6
JournalPediatric Blood and Cancer
Volume60
Issue number1
DOIs
Publication statusPublished - Jan 2013

Fingerprint

Jordan
Rhabdomyosarcoma
Febrile Neutropenia
Cyclophosphamide
Disease-Free Survival
Survival Rate
Therapeutics
Developing Countries
Hospitalization
Developed Countries
Neoplasms
Retrospective Studies
Demography
Survival
Incidence

Keywords

  • Cyclophosphamide
  • Developing countries
  • Rhabdomyosarcoma

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Al-Jumaily, U., Ayyad, O., Masarweh, M., Ghandour, K., Almousa, A., Al-Hussaini, M., ... Sultan, I. (2013). Improved care of rhabdomyosarcoma in Jordan using less intensive therapy. Pediatric Blood and Cancer, 60(1), 53-58. https://doi.org/10.1002/pbc.24241

Improved care of rhabdomyosarcoma in Jordan using less intensive therapy. / Al-Jumaily, Usama; Ayyad, Omar; Masarweh, Main; Ghandour, Khalil; Almousa, Abdelatif; Al-Hussaini, Maysa; Ferrari, Andrea; Sultan, Iyad.

In: Pediatric Blood and Cancer, Vol. 60, No. 1, 01.2013, p. 53-58.

Research output: Contribution to journalArticle

Al-Jumaily, U, Ayyad, O, Masarweh, M, Ghandour, K, Almousa, A, Al-Hussaini, M, Ferrari, A & Sultan, I 2013, 'Improved care of rhabdomyosarcoma in Jordan using less intensive therapy', Pediatric Blood and Cancer, vol. 60, no. 1, pp. 53-58. https://doi.org/10.1002/pbc.24241
Al-Jumaily U, Ayyad O, Masarweh M, Ghandour K, Almousa A, Al-Hussaini M et al. Improved care of rhabdomyosarcoma in Jordan using less intensive therapy. Pediatric Blood and Cancer. 2013 Jan;60(1):53-58. https://doi.org/10.1002/pbc.24241
Al-Jumaily, Usama ; Ayyad, Omar ; Masarweh, Main ; Ghandour, Khalil ; Almousa, Abdelatif ; Al-Hussaini, Maysa ; Ferrari, Andrea ; Sultan, Iyad. / Improved care of rhabdomyosarcoma in Jordan using less intensive therapy. In: Pediatric Blood and Cancer. 2013 ; Vol. 60, No. 1. pp. 53-58.
@article{d5b6b52aa9574c679d2900ab7f4ae2fd,
title = "Improved care of rhabdomyosarcoma in Jordan using less intensive therapy",
abstract = "Background: The care of rhabdomyosarcoma (RMS) is complex due to its multimodal nature. By following standard protocols with acceptable toxicity and building local expertise, better outcome should be achievable. Procedure: A retrospective study was conducted of records of patients (n=45; 31 males; median age 26 months) with RMS treated at King Hussein Cancer Center in Jordan from January 2004 to December 2008. Patient demographics, tumor characteristics, risk stratification, treatment plan, and outcomes were studied. In June 2006, the cyclophosphamide dose was lowered from 2.2g/m2 to 1.2g/m2 per cycle because of the significant toxicity with higher dose. Survival rates, hematological toxicities, period of hospitalization due to febrile neutropenia (FN), and response rate at week 12 of treatment were compared between low- and high-dose cyclophosphamide groups. Results: Four-year progression-free survival (PFS) and overall survival (OS) rates were 61{\%}±7.5{\%} and 72{\%}±6.9{\%}, respectively. There was a significant difference in outcome by risk group in 4-year PFS (low-risk, 88{\%}±12{\%}; intermediate-risk 63{\%}±9.3{\%}; high-risk, 14{\%}±13{\%}; P=0.0001) and OS (low-risk, 88{\%}±12{\%}; intermediate-risk 79{\%}±7.5{\%}; high-risk, 17{\%}±15{\%}; P=0.0011). There was significant reduction in hematological toxicities, incidence of FN, and period of hospitalization for FN in patients given low-dose cyclophosphamide but no significant difference in PFS between low- and high-dose cyclophosphamide groups. Conclusions: Survival rates of patients with RMS in some developing countries can be improved by following or modifying evidence-based approaches successful in developed countries and establishing multidisciplinary strategies. Therapy intensity should be increased in developing countries only when evidence supports its utility.",
keywords = "Cyclophosphamide, Developing countries, Rhabdomyosarcoma",
author = "Usama Al-Jumaily and Omar Ayyad and Main Masarweh and Khalil Ghandour and Abdelatif Almousa and Maysa Al-Hussaini and Andrea Ferrari and Iyad Sultan",
year = "2013",
month = "1",
doi = "10.1002/pbc.24241",
language = "English",
volume = "60",
pages = "53--58",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Improved care of rhabdomyosarcoma in Jordan using less intensive therapy

AU - Al-Jumaily, Usama

AU - Ayyad, Omar

AU - Masarweh, Main

AU - Ghandour, Khalil

AU - Almousa, Abdelatif

AU - Al-Hussaini, Maysa

AU - Ferrari, Andrea

AU - Sultan, Iyad

PY - 2013/1

Y1 - 2013/1

N2 - Background: The care of rhabdomyosarcoma (RMS) is complex due to its multimodal nature. By following standard protocols with acceptable toxicity and building local expertise, better outcome should be achievable. Procedure: A retrospective study was conducted of records of patients (n=45; 31 males; median age 26 months) with RMS treated at King Hussein Cancer Center in Jordan from January 2004 to December 2008. Patient demographics, tumor characteristics, risk stratification, treatment plan, and outcomes were studied. In June 2006, the cyclophosphamide dose was lowered from 2.2g/m2 to 1.2g/m2 per cycle because of the significant toxicity with higher dose. Survival rates, hematological toxicities, period of hospitalization due to febrile neutropenia (FN), and response rate at week 12 of treatment were compared between low- and high-dose cyclophosphamide groups. Results: Four-year progression-free survival (PFS) and overall survival (OS) rates were 61%±7.5% and 72%±6.9%, respectively. There was a significant difference in outcome by risk group in 4-year PFS (low-risk, 88%±12%; intermediate-risk 63%±9.3%; high-risk, 14%±13%; P=0.0001) and OS (low-risk, 88%±12%; intermediate-risk 79%±7.5%; high-risk, 17%±15%; P=0.0011). There was significant reduction in hematological toxicities, incidence of FN, and period of hospitalization for FN in patients given low-dose cyclophosphamide but no significant difference in PFS between low- and high-dose cyclophosphamide groups. Conclusions: Survival rates of patients with RMS in some developing countries can be improved by following or modifying evidence-based approaches successful in developed countries and establishing multidisciplinary strategies. Therapy intensity should be increased in developing countries only when evidence supports its utility.

AB - Background: The care of rhabdomyosarcoma (RMS) is complex due to its multimodal nature. By following standard protocols with acceptable toxicity and building local expertise, better outcome should be achievable. Procedure: A retrospective study was conducted of records of patients (n=45; 31 males; median age 26 months) with RMS treated at King Hussein Cancer Center in Jordan from January 2004 to December 2008. Patient demographics, tumor characteristics, risk stratification, treatment plan, and outcomes were studied. In June 2006, the cyclophosphamide dose was lowered from 2.2g/m2 to 1.2g/m2 per cycle because of the significant toxicity with higher dose. Survival rates, hematological toxicities, period of hospitalization due to febrile neutropenia (FN), and response rate at week 12 of treatment were compared between low- and high-dose cyclophosphamide groups. Results: Four-year progression-free survival (PFS) and overall survival (OS) rates were 61%±7.5% and 72%±6.9%, respectively. There was a significant difference in outcome by risk group in 4-year PFS (low-risk, 88%±12%; intermediate-risk 63%±9.3%; high-risk, 14%±13%; P=0.0001) and OS (low-risk, 88%±12%; intermediate-risk 79%±7.5%; high-risk, 17%±15%; P=0.0011). There was significant reduction in hematological toxicities, incidence of FN, and period of hospitalization for FN in patients given low-dose cyclophosphamide but no significant difference in PFS between low- and high-dose cyclophosphamide groups. Conclusions: Survival rates of patients with RMS in some developing countries can be improved by following or modifying evidence-based approaches successful in developed countries and establishing multidisciplinary strategies. Therapy intensity should be increased in developing countries only when evidence supports its utility.

KW - Cyclophosphamide

KW - Developing countries

KW - Rhabdomyosarcoma

UR - http://www.scopus.com/inward/record.url?scp=84870156788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870156788&partnerID=8YFLogxK

U2 - 10.1002/pbc.24241

DO - 10.1002/pbc.24241

M3 - Article

VL - 60

SP - 53

EP - 58

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 1

ER -